PfizerPFEEarnings & Financial Report
Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered at The Spiral in Manhattan, New York City. Founded in 1849 in New York by German entrepreneurs Charles Pfizer (1824–1906) and Charles F. Erhart (1821–1891), Pfizer is one of the oldest pharmaceutical companies in North America.
Revenue
$17.7B
Gross Profit
$12.4B
Operating Profit
$4.7B
Net Profit
$4.5B
Gross Margin
70.3%
Operating Margin
26.6%
Net Margin
25.2%
YoY Growth
39.0%
EPS
$0.78
Pfizer Q3 FY2024 Financial Summary
Pfizer reported revenue of $17.7B (up 39.0% YoY) for Q3 FY2024, with a net profit of $4.5B (up 91.9% YoY) (25.2% margin). Cost of goods sold was $5.3B, operating expenses totaled $7.7B.
Key Financial Metrics
| Total Revenue | $17.7B |
|---|---|
| Net Profit | $4.5B |
| Gross Margin | 70.3% |
| Operating Margin | 26.6% |
| Report Period | Q3 FY2024 |
Revenue Breakdown
Pfizer Q3 FY2024 revenue of $17.7B breaks down across 7 segments, led by Primary Care at $9.1B (51.2% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Primary Care | $9.1B | 51.2% |
| International Commercial Division | $5.4B | 30.7% |
| Total Alliance Biopharmaceuticals | $1.9B | 10.7% |
| Paxlovid NDA Labeled US Strategic National Stockpile | $442.0M | 2.5% |
| Royalty | $384.0M | 2.2% |
| Pfizer Centre One | $285.0M | 1.6% |
| Pfizer Ignite | $25.0M | 0.1% |
Pfizer Revenue by Segment — Quarterly Trend
Pfizer revenue by segment across the last 4 reported quarters, showing how each business line (such as Primary Care and International Commercial Division) has evolved quarter over quarter.
| Segment | Q1 FY2026 | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 |
|---|---|---|---|---|
| Primary Care | — | — | $7.6B | $5.5B |
| International Commercial Division | — | — | $5.7B | $5.5B |
| Total Alliance Biopharmaceuticals | — | $2.6B | $2.3B | $2.3B |
| Royalty | — | $480.0M | $436.0M | $426.0M |
Pfizer Annual Revenue by Year
Pfizer annual revenue history includes year-by-year totals (for example, 2025 revenue was $62.6B).
| Year | Annual Revenue |
|---|---|
| 2025 | $62.6B |
| 2024 | $63.6B |
Pfizer Quarterly Revenue & Net Profit History
Pfizer results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2026 | $14.5B | +5.0% | $2.7B | 18.6% |
| Q4 FY2025 | $17.6B | -1.2% | $-1.6B | -9.4% |
| Q3 FY2025 | $16.7B | -5.9% | $3.5B | 21.3% |
| Q2 FY2025 | $14.7B | +10.3% | $2.9B | 19.9% |
| Q1 FY2025 | $13.7B | -7.8% | $3.0B | 21.6% |
| Q4 FY2024 | $17.8B | +34.2% | $410.0M | 2.3% |
| Q3 FY2024 | $17.7B | +39.0% | $4.5B | 25.2% |
| Q2 FY2024 | $13.3B | -27.3% | $41.0M | 0.3% |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $13.28B | $17.70B | $17.76B | $13.71B | $14.65B | $16.65B | $17.56B | $14.45B |
| YoY Growth | -27.3% | 39.0% | 34.2% | -7.8% | 10.3% | -5.9% | -1.2% | 5.0% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $216.19B | $219.48B | $213.40B | $208.03B | $206.09B | $208.73B | $208.16B | N/A |
| Liabilities | $128.22B | $126.92B | $124.90B | $117.39B | $117.08B | $115.64B | $121.39B | N/A |
| Equity | $87.70B | $92.29B | $88.20B | $90.34B | $88.69B | $92.80B | $86.48B | N/A |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|
| Operating CF | $-1.78B | $6.71B | $6.72B | $2.33B | $-582.0M | $4.60B | $5.35B |